5명의 월스트리트 애널리스트에 따르면, Bioventus Inc의 매출 추정치는 $137.41M에서 $127.23M까지입니다.
Bioventus Inc의 수익 품질 점수는 얼마인가요?
Bioventus Inc의 수익 품질 점수는 B+/53.57558입니다. 이 점수는 수익성, 성장, 현금 창출 및 자본 배분, 레버리지의 네 가지 차원을 기반으로 합니다.
Bioventus Inc는 언제 수익을 보고하나요?
Bioventus Inc의 다음 수익 보고서는 2026-06-03에 발표될 예정입니다.
Bioventus Inc의 예상 수익은 얼마인가요?
월스트리트 애널리스트에 따르면 Bioventus Inc의 예상 수익은 $156.39M입니다.
Bioventus Inc은 수익 기대치를 충족했나요?
Bioventus Inc의 최근 수익은 $157.9M로, 기대치를 뛰어넘다.
주요 통계
이전 종가
$9
시가
$8.9
일일 범위
$8.9 - $9.29
52주 범위
$5.81 - $9.98
거래량
381.8K
평균 거래량
311.7K
배당수익률
--
EPS(TTM)
0.33
시가총액
$760.8M
BVS란 무엇인가요?
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 930 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.